Glenmark Pharmaceuticals Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi, Glenmark
Release Date: 2011-05-16
• Sanofi to develop the molecule for Crohn’s Disease and other antiinflammatory conditions such as Multiple Sclerosis • Combined upfront and potential development, regulatory and commercial milestone payments could total US$613 Mn
| Type: | NORMAL |
| Company: | Glenmark |
| Country: | 印度 |
| Url: | http://www.glenmarkpharma.com/GLN_NWS/PDF/Glenmark_-_GBR_500_Press_Release.pdf |